Advertisement

Pituitary

, Volume 13, Issue 4, pp 345–350 | Cite as

Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature

  • Graciela Stalldecker
  • María Susana Mallea-Gil
  • Mirtha Guitelman
  • Analía Alfieri
  • María Carolina Ballarino
  • Laura Boero
  • Alberto Chervin
  • Karina Danilowicz
  • Sabrina Diez
  • Patricia Fainstein-Day
  • Natalia García-Basavilbaso
  • Mariela Glerean
  • Viviana Gollan
  • Débora Katz
  • Mónica Graciela Loto
  • Marcos Manavela
  • Amelia Susana Rogozinski
  • Marisa Servidio
  • Nicolás Marcelo Vitale
Article

Abstract

The aim of the study is to assess the rate of any potential adverse effects on women who became pregnant under cabergoline (CAB) treatment and to evaluate any effects on the embryo-fetal development and on children who were born from mothers exposed to CAB in early weeks of gestation. Observational, retrospective and multicenter study on 103 pregnancies in 90 women with hyperprolactinemia. All patients were under CAB at conception. Serum prolactin at baseline was between 30 and 1921 ng/ml. Duration of therapy before pregnancy ranged from 1 to 120 months and doses ranged from 0.125 to 5 mg/week. Fetal exposure ranged from 3 to 25 weeks, 96.9% of patients received CAB during the first trimester of pregnancy and the rest until the second one. No significant complications during pregnancy were found. Seven women (7.2%) had spontaneous abortions. Preterm deliveries were recorded in eight (8.8%), only one with low weight for gestational age. Neonatal abnormalities were observed in 3 (3.6%): 1 major (Down syndrome) and 2 minor malformations (umbilical and inguinal hernia). We were able to asses the children’s development in 61. Two had epilepsy and two had Pervasive Developmental Disorder (PDD). No significantly higher frequency of complications was found in pregnancies and/or offspring exposed to CAB than in the normal population. We registered 2 abnormalities in the development of the children: epilepsy and PDD. Larger series of patients are needed to assess the safety of this drug during pregnancy.

Keywords

Cabergoline Pregnancy Hyperprolactinemia Drug adverse effects 

Notes

Acknowledgments

We would like to thank Dr José Luis Alonso for his encouragement and help in the obstetric area. We are grateful to Ms Claudia Muschitiello for her assistance in the English version. We deeply thank Dr Marina Mauro for her assistance in the manuscript. The following hospitals of Buenos Aires City participated in this study: Pirovano, Militar Central, Durand, Posadas, Clínicas José de San Martín, Rivadavia, Santa Lucía, Italiano, FLENI, Británico, Ramos Mejia, Alvarez.

References

  1. 1.
    Mah PM, Webster J (2002) Hyperprolactinemia: etiology, diagnosis and management. Semin Reprod Med 20(4):365–374CrossRefPubMedGoogle Scholar
  2. 2.
    Molitch ME (1999) Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 28(1):143–169CrossRefPubMedGoogle Scholar
  3. 3.
    Turkalj I, Peter Braun P, Krupp P (1982) Surveillance of bromocriptine in pregnancy. JAMA 247(11):1589–1591CrossRefPubMedGoogle Scholar
  4. 4.
    Molitch ME (1999) Management of prolactinomas during pregnancy. J Reprod Med 44(12):1121–1126PubMedGoogle Scholar
  5. 5.
    Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485–534CrossRefPubMedGoogle Scholar
  6. 6.
    Ferrari C, Mattei A, Melis GB, Paracchi A, Muratori M, Faglia G, Sghedoni D, Crosignani PG (1989) Cabergoline: long-acting oral treatment of hiperprolactinemic disordes. J Clin Endocrinol Metab 68:1201–1206CrossRefPubMedGoogle Scholar
  7. 7.
    Ciccarelli E, Giusti M, Miola C, Potenzoni F, Sghedoni D, Camanni F, Giordano G (1989) Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab 69:725–728CrossRefPubMedGoogle Scholar
  8. 8.
    Ricci E, Parazzini F, Motta T, Ferrari C, Colao A, Clavenna A, Rocchi F, Gangi E, Paracchi S, Gasperi M, Lavezzari M, Nicolosi A, Simona Ferrero S, Landi M, Beck-Peccoz P, Bonati M (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 16(6):791–793CrossRefPubMedGoogle Scholar
  9. 9.
    Robert E, Musatti L, Piscitelli G, Ferrari C (1996) Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 10:333–337CrossRefPubMedGoogle Scholar
  10. 10.
    Colao A, Abs R, Gonzalez Bárcena D, Chanson P, Paulus W, Kleinberg D (2008) Pregnancy outcomes following cabergoline treatment: extended results from a 12- year observational study. Clin Endocrinol (Oxf) 68(1):66–71CrossRefGoogle Scholar
  11. 11.
    Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, Takano K, Izumi SI, Okada Y, Hori T (2010) Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 95:2672–2679CrossRefPubMedGoogle Scholar
  12. 12.
    Lebbe M, Hubinont C, Bernard P, Maiter D (2010) Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol (Oxf) Apr 23 (Epub ahead of print) PMID:20455894Google Scholar
  13. 13.
    Guillam P, Fideleff H, Boquete HR, Molitch ME (2004) Prolactin excess: treatment and toxicity. Ped Endocrinol Rev 2(Suppl1):108–114Google Scholar
  14. 14.
    Colao A, Loche S, Cappa M, Di Sarno A, Landi MA, Sarnacchiaro F, Facciolli G, Lombardi G (1998) Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 83:2777–2780CrossRefPubMedGoogle Scholar
  15. 15.
    Stalldecker G, Mallea Gil MS, Guitelman M, Alfieri A, Ballarino MC, Boero L, Carabelli MA, Cornaló D, Chervin A, Danilowicz K, Fainstein Day P, García Basavilbaso N, Glerean M, Goyan V, Katz D, Loto MG, Manavela M, Nahmías JA, Rogozinski AS, Servidio M, Vitale NM (2010) Estudio Retrospectivo sobre las Posibles Complicaciones Materno-Fetales de la Exposición a Cabergolina. RAEM 47 (in press)Google Scholar
  16. 16.
  17. 17.
    Nazer Herrera J. Frecuencia de malformaciones en ECLAMC-Chile y en resto del ECLAMC www.redclinica.cl/html/archivos/30.pdf
  18. 18.
    Zarante Montoya I, Castillo MC, García N, Suárez F, Gutiérrez CA, Umaña A (2002) Análisis clínico epidemiológico de factores asociados a malformaciones congénitas ECLAMC-Hospital Universitario San Ignacio junio- diciembre 2001 UNIVMED 43(2)Google Scholar
  19. 19.
    Webster J, Piscitelli G, Polli A, Ferrari CI, Ismael I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331:904–909CrossRefPubMedGoogle Scholar
  20. 20.
    Cannavó S, Curtó L, Squadrito S, Almoto B, Vieni A, Trimarchi F (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactine–secreting pituitary adenoma. J Endocrinol Invest 22:354–359PubMedGoogle Scholar
  21. 21.
    Verhelst J, Abs R, Maiter D, Van den Bruel A, Vandeweghe M, Velkeniers B, Movkel J, Lamberrigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518–2522CrossRefPubMedGoogle Scholar
  22. 22.
    Ciccarelli E, Grottoli S, Razzore P, Gaia D, Bertagna A, Cirillo S, Cammarota T, Camanni M, Camanni F (1997) Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J Endocrinol Invest 20(9):547–551PubMedGoogle Scholar
  23. 23.
    Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M (2000) Maternal age fetal loss: population based register linkage study. BMJ 320:1708–1712CrossRefPubMedGoogle Scholar
  24. 24.
    Forsbach-Sánchez G, Tamez-Pérez HE, Hernández-Herrera R, Bafidis-Lechuga B (2009) Tratamiento del macroprolactinoma con cabergolina durante el embarazo. Rev Med Inst Mex Seguro Soc 47(3):307–310PubMedGoogle Scholar
  25. 25.
    Jones J, Bashir T, Olney J, Wheatley T (1997) Cabergoline treatment for a large macroprolactinoma throughout pregnancy. J Obst Gynaecol Vol. 17(4):375–376CrossRefGoogle Scholar
  26. 26.
    Liu C, Tyrrell B (2001) Successful treatment of a large macroprolactinoma with cabergoline during pregnancy. Pituitary 4:179–185CrossRefPubMedGoogle Scholar
  27. 27.
    Laloi-Michelin M, Ciraru-Vigneron N, Meas T (2007) Cabergoline treatment of pregnant women with macroprolactinomas. Int J Gynaecol Obstet 99(1):61–62CrossRefPubMedGoogle Scholar
  28. 28.
    Sharma JB, Roy KK, Mohanraj P, Kumar S, Karmakar D, Barua J (2009) Pregnancy outcome in pituitary tumors. Arch Gynecol Obstet 280:401–404CrossRefPubMedGoogle Scholar
  29. 29.
    Banerjee A, Wynne K, Tan T, Hatfield EC, Martin M, Williamson C, Meeran K (2009) High dose cabergoline therapy for a resistant macroprolactinoma during pregnancy. Clin Endocrinol(Oxf) 70(5):812–813CrossRefGoogle Scholar
  30. 30.
    Jones TH, Fraser RB (1994) Cabergoline treated hyperprolactinaemia results in pregnancy in a bromocriptine intolerant patient after seventeen years of infertility. Br J Obstet Gynaecol 101:349–350PubMedGoogle Scholar
  31. 31.
    Bronstein MD, Salgado LR, Musolino NR (2002) Medical management of pituitary adenomas: the special case of the pregnant woman. Pituitary 5:99–107CrossRefPubMedGoogle Scholar
  32. 32.
    La prematurez como problema de salud pública. www.sap.org.ar/docs/institucional/16.pdf
  33. 33.
    Ata B, Seyhan A, Orhane S, Urman B (2009) High dose cabergoline in management of ovarian hyperstimulation syndrome. Fertil Steril 92(3):1168 e1–1168 e4Google Scholar
  34. 34.
    Alvarez C, Alonso-Muriel I, Garcia G, Crespo J, Bellver J, Simon C, Pellicer A (2007) Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Human Reprod 22(12):3210–3214CrossRefGoogle Scholar
  35. 35.
    Carizza C, Abdelmassih V, Abdelmassih S, Ravizzini P, Salgueiro L, Tudech Salgueiro P, Jine LT, Nagy P, Abdelmassih R (2008) Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 17(6):751–755CrossRefPubMedGoogle Scholar
  36. 36.
    Melcon M, Kochen S, Vergara R (2007) Prevalence and clinical features of epilepsy in Argentina. Neuroepidemiology 28(1):8–15CrossRefPubMedGoogle Scholar
  37. 37.
    Somoza M, Forlenza R, Brussino M, Licciardi L (2005) Epidemiological survey of epilepsy in the primary school population in Buenos Aires. Neuroepidemiology 25(2):62–68CrossRefPubMedGoogle Scholar
  38. 38.
    Van Naarden Braun K, Pettygrove S, Daniels J, Miller L, Nicholas J, Baio J, Schieve L, Kirby RS, Washington A, Brocksen S, Rahbar H, Rice C (2007) Centers for Disease Control and Prevention. Evaluation of a methodology for a collaborative multiple source surveillance network for autism spectrum disorders-Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2002. MMWR Surveillance Summaries 56(1):29–40Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Graciela Stalldecker
    • 1
  • María Susana Mallea-Gil
    • 1
  • Mirtha Guitelman
    • 1
  • Analía Alfieri
    • 1
  • María Carolina Ballarino
    • 1
  • Laura Boero
    • 1
  • Alberto Chervin
    • 1
  • Karina Danilowicz
    • 1
  • Sabrina Diez
    • 1
  • Patricia Fainstein-Day
    • 1
  • Natalia García-Basavilbaso
    • 1
  • Mariela Glerean
    • 1
  • Viviana Gollan
    • 1
  • Débora Katz
    • 1
  • Mónica Graciela Loto
    • 1
  • Marcos Manavela
    • 1
  • Amelia Susana Rogozinski
    • 1
  • Marisa Servidio
    • 1
  • Nicolás Marcelo Vitale
    • 1
  1. 1.Departamento de Neuroendocrinología (Neuroendocrinology Department)Sociedad Argentina de Endocrinología y MetabolismoBuenos AiresArgentina

Personalised recommendations